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lievens@ec.europa.eu)The past two decades have witnessed the rise of commercial
crops that have been genetically modified for an increased
suitability in extensive cultivation. Currently, a substantial
body of research is being carried out in order to produce
Genetically Modified (GM) animals that may similarly yield
improvements in animal breeding, genetics and reproduction.
Here, we attempt a comprehensive review of the existing trails
at animal modification with commercial applications and
aimed at a deliberate release onto the market. In addition,
we investigate detection and quantification options within
the frame of food/feed control and traceability on the European
market.Introduction
Over the past 30 years, biotechnological developments have
allowed scientists to alter the genetic make-up of bacteria,
plants, and animals. Initially, these modifications have
served the purpose of basic research (the study of gene
function and genetic mechanisms), but these techniques
quickly became promising tools from agricultural point of
view since they allow the addition of novel traits toopen accorganisms which may increase their suitability for use in
extensive mono-cultures (e.g. animals with better neonatal
survival, or plants with herbicide resistances and insect tol-
erances). The first genetically modified organisms (GMOs)
for agricultural use were introduced in 1996 and currently,
more than 170 million hectares of GM crops are being
cultivated worldwide (James, 2010, 2011) and while genet-
ically modified (GM) animals are not yet in farms or on the
market, their introduction is foreseen for the near future
(Ledford, 2013).
Since the creation of the first GM livestock (Hammer
et al., 1985) effort has been made to modify several aspects
of farm animals to improve their cultivation. Amongst the
most targeted traits are: animal health (increased neonatal
survival (Bleck, White, Miller, & Wheeler, 1998; Tong
et al., 2011; Wheeler, Bleck, & Donovan, 2001), disease
resistance (Denning et al., 2001; Lyall et al., 2011; Richt
et al., 2007), growth rate (Devlin, Sakhrani, Tymchuk,
Rise, & Goh, 2009; Nottle et al., 1999; Saunders,
Fletcher, & Hew, 1998), improvement of meat (Lai et al.,
2006; Saeki et al., 2004) and milk composition (Brophy
et al., 2003; Wu et al., 2012), and increased wool produc-
tion (Bawden, Sivaprasad, Verma, Walker, & Rogers,
1995; Damak, Sul, Jay, & Bullock, 1996). In addition, the
reduction of the impact of animal culture on the environ-
ment has been attempted (Phillips, Golovan, Meidinger,
& Forsberg, 2006). Table 1 includes further examples of an-
imal modifications. Fig. 1 shows an example of the effects
of growth rate modification (AquAdvantageSalmon,
currently considered for approval for the American
market).
Another branch of animal modification is molecular
farming, also known as ‘pharming’, in which bio-
pharmaceuticals are manufactured in transgenic animals
(Kind & Schnieke, 2008). More than recombinant cell cul-
tures, animals are attractive bioreactors: they have the cor-
rect metabolic pathways, are reproducible, easily
maintained, and do not require expensive infrastructure
(Dyck, Lacroix, Pothier, & Sirard, 2003). Production of
these recombinant proteins usually happens in mammalian
milk, since it offers flexible production and relatively
straightforward purification, but also egg white and seminal
plasma are being used (Dyck et al., 2003). Blood, on the
other hand, is usually not able to store high concentrations
of recombinant proteins (Houdebine, 2009b). Another med-
ical application of genetic modification aims to improve theess article under the CC BY-NC-ND license (http://creativecommons.org/
Table 1. Overview of some of the transgenic animals with potential commercial applications (excluding mice and rats). Animals are classified in
three categories: ‘Livestock’, ‘Bioreactor’, and ‘Companion’. Other columns list the main inserted/deleted gene, its origin, and main effect or
use. ‘ID’ is a numerical identifier given to enable straightforward comparison with Table 2. References to literature for each entry can be found
in the supplemental material. This table is adapted from (Forabosco, Lohmus, Rydhmer, & Sundstrom, 2013; Pursel & Rexroad, 1993; Rudolph,
1999; Vazquez-Salat, Salter, Smets, & Houdebine, 2012; Wall, 1999) and has been updated & expanded.
Species Category ID Transgene Origin Effect/Goal
Cattle Livestock 1 Lysozyme Human Milk composition
2 PrP Knockout Animal health
3 a,k-Casein Bovine Milk composition
4 Omega-3 Nemateode Milk composition
5 Lysostaphin Bacterial Mastasis resistance
Bioreactor 6 Lactoferrin Human Prophylactic treatment
Chicken Livestock 7 alv6 enveloppe glycoprotein Viral Disease resistance
8 short hairpin RNA Viral Disease resistance
9 LacZ Bacterial Animal Health
Bioreactor 10 a-interferon Human Hepatitis treatment
Carp Livestock 11 Growth Hormone Piscine Growth rate
12 Lactorferrin Human Disease resistanc
Catfish Livestock 13 Cercopin B Insect Disease resistanc
Fruit Fly Livestock 14 fsRIDL Hymnopteran Pest control
Frog Bioreactor 15 GFP Cnidarian Water purity
Goat Livestock 16 Lysozyme Human-Bovine Animal Health
17 Monosat. fat. acid Rat-Bovine Mastasis resistance
18 MSP(1)42 Plasmodial Malaria vaccine
19 Antithrombin III Human Thrombosis/embolism treatment
20 Tissue plasminogen activator Human-Mouse Anti clotting agent
21 Lactoferrin Human Prophylactic treatment
22 lysosomal acid b-glucosidase Human Gaucher disease treatment
23 Human coagulation factor IX Human Haemophilia treatment
24 Human beta-defensin 3 Human Milk composition
Pig Livestock 25 Phytase E. Coli-Mouse Feed uptake
26 Growth hormone Human-Porcine Growth rate
27 cSKI Chicken Muscle development
28 Lysozyme Human Piglet survival
29 Unsat. fat. acid Spinach Meat composition
30 Omega-3 Nematode Meat composition
31 a-lactalbumin Bovine Piglet survival
32 Mx1 Murine influenza resistance
Bioreactor 33 Factor VIII Human Haemophilia treatment
34 a(1,3)galactosyltransferase knockout Human transplantation
35 N-glycolylneuraminic acid knockout Human transplantation
36 CD59, DAF Human Human transplantation
37 DAF Human Human transplantation
38 hHO-1 Human Human transplantation
39 hHO-1,DAF Human Human transplantation
40 b-D Mamose, GnTIII Human Human transplantation
41 Fibrinogen Human Tissue sealant
42 Haemoglobin Human Transfusion
43 Protein C Human Blood coagulation
44 Albumin Human Human transplantation
Rabbit Bioreactor 45 Calcitonin Salmon Osteoporosis treatment
46 Erythropoietin Human Anemia treatment
47 Superoxide dismutase Human Blood purification
48 Interleukin-2 Human Cancer treatment
49 Tissue plasmogen activator Human Anti Clotting Agent
50 VP2, VP6 Viral Rotavirus vaccine
51 Human Factor VII Human-Mouse-Chicken Haemophilia treatment
52 Growth Hormone Human HGH insufficiency treatment
53 Von Willebrand factor Human-Bovine Haemophilia treatment
Salmon Livestock 54 Growth hormone Piscine Growth rate
55 Growth hormone Piscine Growth rate
56 Lysozyme Piscine Animal health
57 wflAFP-6 Piscine Cold tolerance
Sheep Livestock 58 IGF-1 Ovine Wool growth
(continued on next page)
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Table 1 (continued )
Species Category ID Transgene Origin Effect/Goal
59 CsK Bacterial Wool growth
60 HTT Human Disease model
61 Visna resistance Viral Disease resistance
62 PrP knockout Animal health
63 GGTA1 knockout Human transplantation
Bioreactor 64 Factor IX Human Haemophilia treatment
65 Factor VIII Human Haemophilia treatment
66 a-1-antitrypsin Human Cystic fibrosis treatment
Silkworm Livestock 67 eGFP, DsRed, or mKO Cnidarian Silk color
68 A2S814 Arachnid Silk strength
Bioreactor 69 Fibroin Human Cell adhesive film
70 Crp Canine Inflammation marker
71 TRACP5B Human Inflammation marker
Tilapia Bioreactor 72 Insulin Human Diabetes treatment
Trout Livestock 73 Follistatin Piscine Muscle development
Zebrafish Companion 74 GFP or RFP Cnidarian Fish color
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pigs (Luo, Lin, Bolund, Jensen, & Sorensen, 2012).
Lastly, animals have also been modified to improve, or
rather, add ‘aesthetic’ qualities (Gong et al., 2003; Wan
et al., 2002).
Three categories can thus be defined: GM animals for
human consumption, as medical bioreactors, and as com-
panion animal. As the European Union (EU) Joint Research
Center’s Molecular Biology and Genomics Unit we are
responsible for the scientific assessment and validation of
detection, identification and quantification methods for
GMOs (plant, animal, and bacterial) in food and feed and
are thus primarily concerned with the first category.
While GM animals are not yet produced on a large scale
for human consumption, they are already in US pet shops
(Nash, 2004), they are being used for testing water purity
(Fini et al., 2007; Thienpont et al., 2011) (also see www.
watchfrog.fr), pharmaceuticals from GM animals areFig. 1. Effects of growth rate modification in salmon. AquAdvanta-
geSalmon contains a gene from the Chinook salmon which results
in fish with an increased growth rate, thus reaching market size in
half the time of conventional salmon. Image courtesy of AquaBounty
technologies.currently for sale (Wells, 2010), and at the time of writing,
a decision on the approval of GM salmon on the American
market by the FDA is under way (April 2015). The EU is
the world’s largest trading block for food commodities
and as a result, once GM animals enter the global market,
the likelihood of contamination in the European food chain
increases. At least 3 European countries have already
developed methods to screen for GM animals in the context
of food safety (European Network of GM Laboratories, per-
sonal communication).
Here we attempt to give an overview of the genetic mod-
ifications currently (being) made to animals and the strate-
gies or methods that may be employed in the detection and
quantification of their presence in the food chain. We will
primarily focus on animals designed for human consump-
tion, bioreactor animals (and pets) are not intended to end
up in the food chain as they are usually both rare and valu-
able. As a consequence, the latter do not pose a traceability
problem. Nevertheless, the principles laid out in the
following paragraphs are valid for all GM animals.Genetic modifications in animals
The European Union defines GMOs as Genetically
Modified Organisms, such as plants, animals, and micro or-
ganisms whose genetic characteristics are modified artifi-
cially (i.e. not through “natural” breeding) in order to
give them a new property. In practice this boils down to in-
serting or deleting information in the nuclear DNA of (a)
single cell(s). The latter are then grown/multiplied to ulti-
mately form a complete organism carrying the changes in
each somatic cell.
Transgenesis of animals can be achieved using different
techniques: DNA microinjection, retroviral vectors, intra-
cytoplasmic sperm injection, and somatic cell nuclear
transfer (for an overview see (Houdebine, 2009a; Kues &
Niemann, 2011)). The success rate (live births) of each
technique depends on the species, but is usually in the
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tion and most are limited in the amount of base pairs they
can add to the target genome.
The first generation of these GMOs is hemizygous (only
one copy of the gene is present in an otherwise diploid or-
ganism) as opposed to heterozygous (two different alleles
are present at a gene locus) or homozygous (identical al-
leles are present). For breeding purposes, homozygous or-
ganisms are preferred since their offspring is genetically
homogeneous (guaranteed to pass on a trait). In plants tran-
sition from hemi-to homozygous is a rather straightforward
process of (longterm) inbreeding. In farm animals, more
elaborate and time consuming breeding programs are
required.
Insertion of genetic material
When expression of novel traits or production of pro-
teins is the intended goal, the DNA coding for these prop-
erties has to be added to the host genome. To attain reliable
expression the transgene must be accompanied by: a pro-
moter, enhancers, insulators introns, and a terminator
(Houdebine, 2009a). For GM crops this scheme is well es-
tablished and many plants that express new proteins have
been realized. For example, the expression of insecticidal
proteins yielding an increased innate protection from insect
damage thus reducing the need for the application of pesti-
cides (Nelson & Alves, 2014). In animals, one of the main
applications of protein expression is the production of phar-
macologically important proteins for harvest (animals as
bioreactors, see Table 1 for examples). Excretion of bio-
pharmaceuticals in milk, for instance, can be achieved us-
ing promoters from milk protein genes (e.g. whey acidic
protein), whereas for expression in egg, the promoter of
the ovalbumin gene can be used. Other applications of pro-
tein expression focuss on improving the fitness of animals
in high-density conditions or to alter meat composition (an-
imals as livestock, see Table 1 for examples).
In addition to the introduction of new traits, the insertion
of genetic material can also be used to ‘silence’ genes:
either by expressing short synthetic oligonucleotides with
complementary to the sequence of the mRNA of the tar-
geted gene, preventing its translation, or by expressing
intracellular antibodies against the target protein (intrabod-
ies). Another strategy is to overexpress a gene coding for an
inactive version of the targeted protein.
Deletion of genetic information
Sometimes the removal of a gene (and thus its product)
may be advantageous: e.g. protein PrP which may cause
prion diseases when its misfolded forms are propagated
(cf. Bovine spongiform encephalopathy (Richt et al.,
2007)), myostatin which acts as a downregulator for muscle
growth (cf. Belgian Blue Cattle (Grobet et al., 1997)), or
a(1,3)galactosyl transferase which may cause hyperacute
rejection in xenotransplants (Kuwaki et al., 2005; Lutz
et al., 2013; Yamada et al., 2005).Deletions or ‘knockouts’ can be achieved through ho-
mologous recombination or by use of a recombinase driven
system like Cre-LoxP or Flp-FRT. The latter systems oper-
ate by adding a recombinase site to both ends of the target
fragment, the recombinase can then be synthesized under
the direction of a cell specific promoter, making it possible
to delete a DNA fragment only in a chosen cell type.
Current GM practice
Detection and quantification strategies
For most of the members of the European Network of
GMO Laboratories (ENGL) the workflow surrounding
GM sample processing includes of the following steps:
(I) analysis of the meta information surrounding a sample
in order to decide which screening methods to used (eg.
only markers related to a single crop or a full screening),
(II) run these screening methods and if all are negative
estop the testing, (III) in case of positive results, identify
possible events and run the event specific tests, possibly
quantifying any positive result in the same run, (IV) if no
event specific tests show a positive result, declare the sam-
ple being contaminated with an un-authorised GMO.
Current EU practice in GM quantification is to evaluate
a sample’s GM content on a per ingredient base (i.e. the
percentage GM is expressed, for each ingredient (species),
as fraction of the total amount present in the sample). This
approach allows for a straightforward implementation in a
(real time) PCR set-up. It is, however, not the only option
available: quantification of GM-material could also be ex-
pressed as the fraction of the total material of the entire
group of ingredients/components (e.g. all plant material
in a food product). Another option could be GM material
as fraction of the total material of the food or feed product.
For plant-derived materials, the latter two options currently
not deemed feasible on the basis of DNA.
Amplification methodology
At present, (real time) PCR-based analysis is the method
of choice for the routine analysis of food and feed samples
for their GMO content (Bonfini, Kay, Heinze, & Van den
Eede, 2002; Holst-Jensen, 2009; Zel et al., 2012). These
methods are DNA based and are thus applicable for the
detection of all (GM) organisms. They consist of targeting
specific DNA sequences (between 60 and 200 base pairs
long) for enzymatic amplification, revealing the presence
(amplification) or absence (no amplification) of the target
sequence. By following the amplification process fluoro-
metrically (in real time) quantification of the initial amount
of target sequence becomes possible.
Traditionally, three levels of specificity are distinguished
within GMO-detection methods:
Screening methods target DNA sequences that are
frequently inserted into GMOs, e.g. promoters, terminators,
sequences of genes conferring certain tolerances or resis-
tances. These methods allow the detection of a broad range
of genetically modified organisms, but they do not allow to
163A. Lievens et al. / Trends in Food Science & Technology 44 (2015) 159e176identify with absolute certainty which GM event(s) is (are)
present in the sample.
Construct specific methods target two or more adjacent
genetic elements in a transgene construct by amplifying
their junction. These methods are more informative in
terms of presence or absence of specific events, but cannot
distinguish between different events containing the same
(or similar) constructs.
Event specific methods target the host-transgene DNA
junction. As a consequence, these methods are highly spe-
cific and amplify only a single event. They are usually
applied in downstream confirmation of GM positive
samples.
Detection, identification and quantification of GM
animals
In the following paragraphs we list several aspects of the
method design, sample analysis, and interpretation of re-
sults involved in the establishment of a GM animal detec-
tion and quantification platform. Many of these topics are
not confined to the GM animal field, we will therefore
also summarize the existing approaches in the field of
GM plant detection/quantification in each section. Howev-
er, not all of the strategies and assumptions currently em-
ployed in GM plants may transfer directly to animals.
Possible challenges will be identified where appropriate.
Detection and quantification targets
The different type of DNA modifications can be evalu-
ated for their capability to yield event-specific methods
(also see Fig. 2):
Insertions
Insertions are the most straightforward group of modifi-
cations to detect. Insertion of a foreign sequence into the
host genome inevitably generates two unique junctions.
Even if the donor organism is the same species, the junc-
tions at the insertion sites are wholly unique to the GMOFig. 2. Schematic overview of detection targets. DNA is represented in differ
deletions as the omission of grey coloured stretches of DNA, orange is used t
of modification (insertion, deletion and deletion by recombinase) there are d
construct specific detection (square cross-hairs). (For interpretation of the refe
version of thisand specific detection is possible. In addition, targeting
genes or genetic elements inside the insertion may yield
construct specific and screening methods. The success of
such screening strategies will largely depend on the origin
of the inserted elements and whether its presence in the
food chain may cause false-positive screening results.
Deletions
Deletions may not be detected by screening or construct
specific methods. However, similar to insertions, the
removal of sequences usually creates a new, unique, junc-
tion that may be targeted for amplification, thus rendering
the event detectable. Theoretically, exceptions are possible
if the deletion took place in a high-repeat region, this might
create an undetectable (i.e. non-unique) junction region.
However, it should be stressed that this is a statistically
highly unlikely scenario. In addition, a deletion that is
hard to detect is usually not interesting from the point of
GM production because it may complicate screening for
successful deletion in the early stages of the production
process when the modification is attempted on a large num-
ber of cells.
Recombinase
Recombinase mediated deletions form a more heteroge-
neous group of modifications. Depending on the nature of
the construct, the resulting organism may or may not be
mosaic for the deletion. In the latter case targeting either
the pre- or post-deletion border may not suffice to ensure
detection and both sites should be screened for in parallel.
Another possibility is targeting the insertion of the recom-
binase gene. But again, depending on the case, this may not
yield event-specific detection. In research it is common to
have two lines of mutants: one containing the
recombinase-gene, the other containing the deletion-
targeted genes. It is the offspring of these two lines which
then form the functional mutants. It is thus possible to
generate many different GM animals whose genomes allent colours for explanatory purpose. Insertions are represented in red,
o help indicate the new junction after deletion. Depending on the type
ifferent options for event specific identification (circular cross-hairs) or
rences to colour in this figure legend, the reader is referred to the web
article.)
Fig. 3. GMO quantification strategy. Real time PCR detection is carried out for two targets: a wild type endogene and an event specific transgene.
Both reactions are performed on dilution series of a reference material (calibration curves) and on the actual sample. The calibration curves then
allow the calculation of the GM content of the sample.
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nase gene. However, it is currently unclear if this practice
will be applied in livestock.
Quantification
Quantification involves the parallel detection of two tar-
gets: a wild type endogene and an event specific transgene
(both present in one copy per haploid genome). In addition,
calibration curves for both genes are constructed using
reference materials. The whole of results then allows accu-
rate quantification of the GM content of the sample (see
Fig. 3). In current GM quantification strategies, the GM-
unique junction regions are used for the purpose of quanti-
fication. And as explained in the above, similar targets are
expected to be present in GM animals. However, in some
cases, difficulties may be caused by the number of trans-
gene copies per haploid genome. Plants are usually homo-
zygous for the transgene construct, containing exactly one
transgene target per haploid genome copy. However, for an-
imals this may not always be the case: as mentioned above,
certain recombinase-mediated deletion strategies employ
two parental lines of GM animals to create a double hemi-
zygous offspring as functional GM. All of this can be coped
with when making the calculations, provided the informa-
tion is available. One remaining drawback is that, in such
cases, the limit of quantification is doubled since there
are only half as many PCR targets available.
Availability of sequence information
The availability of sequence information is of paramount
importance in order to design detection methods and to
exclude cross-reactivity. Current EU legislation foresees
the producer/applicant to provide this information whenapplying for market access, along with specific identifica-
tion and quantification methods for the event under evalua-
tion. The latter are in turn validated by EU-Reference
Laboratory for GM Food and Feed (EU-RL GMFF). For
a review of the current EU GMO policy see Davison
(2010), Devos et al. (2013)).
The sequence information the producer/applicant has to
provide is the complete sequence of the insertion site, i.e.
the sequence of the transgenic insert (usually called event
sequence) and its flanking genomic sequences (referred to
as the 5- and 3-prime flanking regions). This information
allows the in silico verification of both the method’s speci-
ficity and its possible cross-reactivity with previous or
future detection methods for other events. Moreover, if
multiple transgenic insertion sites were created, they should
all be provided, together with their flanking regions.
For the current generation of GM animals, in spite of the
high number of publications reporting successful transfor-
mations, very little sequence information was found to be
readily available. For this reason, starting from the refer-
ences shown in Table 1, a literature and patent-database
search was carried out. In a few cases the main publication
itself provided useful sequence information, but in most
cases we had to resort to tracing the origin of the inserted
sequence mentioned by its GenBank sequence id, gene or
construct name and references to other publications. While
the ultimate goal is always to find the full event sequence,
also partial sequences like the sole flanking regions or the
inserted gene or construct can prove very useful. The result
of this research is presented in Table 2 .
In practically none of the cases there was a well-defined
reference or pointer to the actual sequence used. Most pub-
lications report the sequence used as a construct that is the
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lication. However, the latter publication then usually cites
another publication that in turn cites another one and so
on. In some cases the chain of references goes back more
than thirty years, to periods when sequencing was very
difficult and the reliability of the reported sequence infor-
mation is highly doubtful.
Even the exact extra-genic gene that has been used is in
many cases difficult to retrieve: often its sequence was
derived as cDNA from reverse transcription-PCR experi-
ments and used directly, in some occurrences without
even sequencing it. In other cases, the sequence was ob-
tained before the availability of the complete genome of
the donor animal or host animal and as a consequence no
similarity comparison was made in order to verify the pres-
ence of single nucleotide polymorphisms or non-synonym
variants in the inserted sequence.
Another facet of the current generation of GM-animals
that became apparent during this literature review, is that
the number of integrated genes is often very high. In
some cases it is even extremely high. Examples are the cat-
tle carrying the cattle a- and k-casein gene, where 84 extra
copies of the bovine beta-casein gene are predicted to be
present (Brophy et al., 2003), and the case of the trout
with more than 200 transgenes copies arrayed head-to-tail
spread over four or five different insertion loci (Wu, Sun,
Wang, Wang, & Zhu, 2005).
Species markers
A crucial point in the current identification strategies us-
ing real time PCR, is the requirement for highly specific en-
dogene markers that show no cross-reactivity with other
species and are able to detect all (commercial) varieties
and/or sub-species of the given organism. On this basis,
many PCR based detection and identification strategies
for animal ingredients have already been published (see
Table 3 for examples) and the identification of (non-
GMO) animal ingredients in processed foods by means of
PCR has been gaining importance, most notably in the field
of food authentication.
Most existing strategies in this field rely on the identifi-
cation of animal species by targeting their mitochondrial
DNA (see Table 3). For achieving high sensitivity, the latter
is an ideal target as it is present in many copies per cell and
since mitochondria may remain intact during certain forms
of processing (Unseld, Beyermann, Brandt, & Hiesel,
1995). Both of these properties increase the probability of
detection in highly processed or severely inhibited DNA
samples. However, this also means that these methods are
at best semi-quantitative since the number of mitochondria
per cell may vary widely between cells and tissues.
Nevertheless, identification alone is often suffices when
the presence or absence of a given species is relevant. This
is, for example, the case for allergens (e.g. hazelnut in cake)
and food fraud (e.g. horse meat in beef burgers). In addi-
tion, the presence of certain ingredients may be essentialfor consumers in order to choose certain foods over others
in a reflection of lifestyles (e.g. vegan, vegetarian) or reli-
gious practices (e.g. kosher, halal). In this regard,
sequencing in combination with bioinformatics is a versa-
tile tool for detecting highly specific sequences in relevant
species that may serve as PCR targets for detection and
identification, especially highly conserved regions (HCR).
The above underscores the difficulty of obtaining correct
sequence information in the absence of reliable, confiden-
tial, producer/applicant provided sequences. Although it
seems unlikely that any of these ‘first generation’ research
focussed GM-animals will find their way onto the market,
we could scarcely find any mention of follow-up or of the
fate of these animals.
In addition to a GM-specific target, the DNA-based
quantification of a sample’s GM-content requires an endog-
enous (wild type) target sequence that is both species spe-
cific (no cross reactivity with other ingredients) and
preferable present in a single copy per haploid genome.
Such targets are typically found in HCR of the genome re-
gions, but the identification of such sequences and the veri-
fication of their suitability for quantification purposes will
require significant effort.
Availability of reference materials
Another crucial point in the quantification of GM con-
tent using standard real-time PCR is the availability of
certified reference materials (CRM), without which the
measurement uncertainty dramatically increases. Generally
speaking, since quantification is done by comparison to a
standard, a quantification result is only as good as the stan-
dard that has been used. Materials of high purity and well-
defined GM content (either in target copy numbers or
weight percentage) are paramount in the process of effi-
ciently enforcing a labelling threshold.
For GM plants, most reference materials are currently
provided by the European Commission’s Institute for
Reference Materials and Methods (IRMM, Belgium) and
the American Oil Chemists’ Society (AOCS, Boulder IL).
As long as no alternative approaches are developed, quan-
tification of GM animal material in the food chain without
the availability of similar reference materials will be diffi-
cult. However, there are several technologies that may pro-
vide absolute quantification in the absence of CRMs (e.g.
digital PCR) but none of these are currently routinely em-
ployed in control laboratories across Europe.
Equivalence of DNA ratio and mass percentage
The current quantification approach of the GM (plant)
content of food and feedstuffs is based on the assumption
of equivalent DNA extraction from all sample ingredients.
In other words: the percentage of GM target relative to a
species specific target as observed in DNA copies is equiv-
alent to the weight/weight percentage of GM in the ingre-
dient of the original sample. Even though there are many
factors that may complicate this assumption (cell size
Table 2. Overview of the sequence availability of the GM animals listed in Table 1. ‘ID’ is a numerical identifier given to each example to enable straightforward comparison with Table 1. The
table indicates whether the junctions between host genome and transgene constructs (so-called event sequence) are currently available or not. In addition, the table lists the accession
number(s) of the inserted sequence(s), the sequences’ origin (Sequence type), and any relevant patents found.
Species ID Involved gene Event sequence
available?
Accession number(s) Sequence type Relevant patent Comments
Cattle 1 hlz, Human lysozyme No X14008.1 Genomic CN-1891821-B Multiple copies were inserted
2 Prp, cattle prion protein No BTU63637; AY221099 Genomic US-2011-0231943-A1 e
3 CSN2, cattle b-casein; CSN3,
cattle k-casein
No NM_181008.2; NM_174294.2 Genomic e Multiple copies were inserted
(up to 84 for CSN2)
4 C. elegans mfat-1 n-3 fatty acid
desaturase
No NM_001028389 cDNA CN-103074347-A Humanized mfat-1 gene
present in the patent
5 S. aureus lysostaphin No AR649720.1 Genomic US-6875903-B2 Modified gene never
sequenced
6 hLf, Human lactoferrin Yes1 U95626 Genomic CN-1873001-A Contains multiple copies of the
incomplete target gene and the
vector backbone
Chicken 7 alv, avian leukosis virus No AF257657.1 cDNA US-H001065-H e
8 decoy hairpin RNA expression
cassette
Yes1 e Synthetic e One insertion site on
chromosome 2
9 lacZ, beta-galactosidase from
retrotransposon vector
No AF062997.1 Genomic e beta-galactosidase from a
retrotransposon vector
10 TPD IFN-a 2b, recombinant
transgenic poultry derived
interferon-a 2b
No GZ791535.1 Synthetic US-8372956-B2 Codon optimized cDNA
derived from human
Carp 11 hGH, Human growth hormon
gene, with introns 2, 3 and 4
deleted
Partially1 e Genomic e Multiple copies were inserted
(more than 200) in 4e5
different loci
12 hLf, Human lactoferrin No U95626 cDNA e Plasmid used in transformation
is pCAgcGH
Catfish 13 HCECB, cecropin B No EA072598 Synthetic US-7183079-B2
Fruit Fly 14 Cctra, Ceratitis capitata
transformer intron
No CS802232.1 Genomic WO-2007091099 the sequence from CS802232.1
is present in the patent, but it is
identical to a sequence
provided as supplemental
material in (Fu et al., 2007)
Frog 15 eGFP, enhanced green
fluorescent protein; chicken
lysozyme gene promoter region
No X98408.1 cDNA and genomic US 8476484 B2 X98408.1 corresponds to the
chicken lysozyme gene
promoter region
Goat 16 hlz, Human lysozyme; bovine
kappa casein
No NA cDNA US-7199281-B2 e
17 scd, rat stearoyl CoA desaturase No NM_031841.1; X14710.1 cDNA US-244874-B2 Expression controlled by the
bovine b-lactoglobulin
promoter (X14710.1)
18 msp-1, merozoite surface
protein-1
No AX686827.1 cDNA WO-2002058727-A2 MSP-1 sequence present in the
patent
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19 rhAT, recombinant Human
antithrombin cDNA
No e cDNA EP-0256302-A2 cDNA derived from a modified
pBAT6 plasmid (sequence in
patent)
20 LAtPA, Human longer acting
tissue plasminogen activator
No e e e LAtPA is mentioned as being a
modified version the human
version and is under control of
the murine whey acid promoter
(WAP)
21 hLf, Human lactoferrin No X53961 cDNA e Multiple copies are inserted.
22 hGCase, Human beta-
glucosidase
No M16328 cDNA e e
23 hFIX, Human coagulation
factor IX
No e cDNA e e
24 HBD3, Human beta defensin
103B
No e Genomic CN 101591672 B Patent refers to transgenic
cows, but sequence n.1 is the
HBD3 described in the article
Pig 25 AppA, E. coli phytase Yes AR986122 Genomic US-7115795-B1 Expression controlled by the
murine parotid secretory
protein (PSP) promoter/
enhancer
26 Porcine growth hormone No e US-5573933-A Human metallothionein-IIA
promoter fused to porcine
growth hormone. Sequence
may be extracted from the
patent.
27 c-ski, chicken c-ski protein
gene
No M28517.1 Genomic US-6218596-B1 e
28 hlz, Human lysozyme No X14008.1 Genomic CN 1891821 B cDNA with 2 copies of chicken
b-globin insulator and one
copy of the goat b-casein
promoter. Two different GM-
pigs were produced: one
described in (Tong et al., 2011)
where hLZ expression levels
were low; a second one
described in (Lu et al., 2014)
that used the same construct
of (Yang et al., 2011),
successful for GM-cattles.
29 FAD2, spinach fatty acid
desaturase
No AB094415 cDNA US-2006-0282907-A1 Construct contains 2 mouse
AP2 promoter regions. In the
patent a slightly different
sequence from spinach is
reported.
(continued on next page)
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Table 2 (continued )
Species ID Involved gene Event sequence
available?
Accession number(s) Sequence type Relevant patent Comments
30 hfat-1, humanized
Caenorhabditis elegans gene
No DJ417997.1 Genomic US-2007-0274952-A1 Expression controlled by the
chicken bactin promoter.
31 alpha-LA, bovine alpha-
lactalbumin gene
EA061936.1 Genomic US-7169963-B2
32 mouse Mx1 cDNA No e cDNA The authors published the
sequence of Sus scrofa Mx1
gene (X54328.1, X54329.1,
X54330.1)
33 Human factor VIII No e cDNA US-5880327-A
34 GGTA1, sus scrofa alpha-
galactosyltransferase 1
No NM_213810.2 cDNA e Sequence knockout, actually
no new gene inserted
35 CMAH, sus scrofa
monophosphate-N-
acetylneuraminic acid
hydroxylase
No NM_001113015.1 cDNA e Sequence knockout, actually
no new gene inserted
36 Human membrane cofactor
protein (MCP); Human decay
accelerating factor (DAF);
Human CD59 complement
regulatory protein
No e cDNA US-6166288-A The promoter sequences are
reported in the patent (SEQ ID
3 and SEQ ID 4)
37 hDAF, Human decay
accelerating factor
No AB025019.1 Genomic US-6825395-B1 Also known as CD55 gene. In
the patent the porcine promoter
is reported as SEQ ID 1, that is a
fragment derived from
AB025019.1
38 hHO-1, Human heme
oxygenase-1
No cDNA US-7378569-B2 e
39 hDAF, Human decay
accelerating factor (hDAF);
hHO-1, Human heme
oxygenase-1 (hHO-1)
No NM_000574; NM_002133 cDNA US-7378569-B2 e
40 GnT-III, Human N-
acetylglucosaminyltransferase
III
No e Genomic US-7378569-B2 In the patent the authors also
described the GnTIII gene
under the control of the DAF
promoter
41 Human fibrinogen A chain,
Human heterologous
fibrinogen B chain and human
gamma chain
No e cDNA US-7435869-B2 e
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42 Mutated human alpha globin;
mutated human beta globin
No e Genomic WO-1993-025071-A1 In the patent, it is stated that the
inserted human genes carry one
or more mutations to increase
the level of human
haemoglobin dimers in
transgenic pigs
43 Human protein C No e cDNA US-5589604-A e
44 Human albumin; green
fluorescence protein
No e cDNA e e
Rabbit 45 sCT, salmon calcitonin No e Synthetic US-6211427-B1 In the article the authors
describe a human alpha
lactalbumin joined by an
enterokinase cleavable linker to
salmon calcitonin
46 Human erythropoietin No Z48305.1 Synthetic e Z48305.1 record corresponds
to B.taurus gene for beta-
lactoglobulin variant B. In fact
in the article the authors
describe a bovine beta-
lactoglobulin variant B gene
with an in-frame inserted
human erythropoietin cDNA.
47 Human EC-SOD, extracellular
superoxide dismutase
No BC014418.1 cDNA US-6025540-A Sequence SEQ ID 1 of the
patent is part of sequence
Genbank: BC014418.1
48 hIL2, Human interleukin-2 No e Genomic e e
49 htPA, Human tissue
plasminogen activator
No e cDNA CU-22365-A1 e
50 VP2, VP4, VP6 and VP7
retroviral proteins
No e Synthetic US-2010-0028371-A1 In the patent, several
mutagenized sequence
versions of the VP cDNAs are
present.
51 Human factor VII No M13232; M13438; U78775;
J00440
cDNA US-2011-0059510 -1 1 integration site mapped on
the q26-27 telomere region of
chromosome 7q
52 hGH, Human grow factor No M13438 Genomic e cDNA with ovine alpha-S1
casein (bCSN1S1) promoter
and bovine growth hormone
(bGH) polyadenylation signal
sequences
(continued on next page)
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Table 2 (continued )
Species ID Involved gene Event sequence
available?
Accession number(s) Sequence type Relevant patent Comments
53 vWF, Von Willebrand factor No e Genomic US-6255554-B1 Expression controlled by the
ovine alpha-S1 casein
(bCSN1S1) promoter and
bovine growth hormone (bGH)
polyadenylation signal
sequences
Salmon 54 Salmon growth hormone Partially1 AR093231.1 Genomic US-5998697-A Multiple copies inserted in one
locus. Flanking sequence in
(Uh, Khattra, & Devlin, 2006)
55 Salmon growth hormone Yes1 AY594644 Genomic EP-0578653-B1 Flanking sequence published in
(Yaskowiak, Shears, Agarwal-
Mawal, & Fletcher, 2006) and
also present in patent
56 lyzII, trout lysozyme II No X59491 cDNA e In (Fletcher et al., 2011) the
sequence of the full construct is
reported in Fig. 2
57 AFP, antifreeze protein Partially1 AR222424 cDNA US-6429293-B1 Flanking sequence is reported
in Fig. 1C of the article.
Sheep 58 IGF-1, ovine insulin-like
growth factor 1
No e cDNA AU-1996-050613-A The IGF-1 is from ovine origin
and it was linked to the mouse
ultra-high-sulfur keratin
promoter
59 cysK, S.typhimurium cysteine
synthase A
No M21450.1 Genomic US-5360742-A
60 HTT, Human huntingtin No FJ457100 cDNA US-2009-0304595-A1 In the patent a pig model is
described.
61 Visna virus No M10608.1 Genomic e e
64 hFIX, Human coagulation
factor IX
No K02402.1 Genomic US-6344596-B1
WO-1990-005188-A1
WO-1988-000239-A1
At least three different
transgenic sheep carrying hFIX
been created by different
authors. The authors of the
patent US-6344596-B1 are not
the same of the cited
references. Patent WO
1990e005188 A1 refers
to (Clark et al., 1989).
In (Schnieke et al., 1997) a
PGKneo marker gene is also
described as inserted.
65 hFVIII, Human coagulation
factor VIII
No e cDNA WO-1996-009377-A1 More than one transgenic
sheep carrying hFVIII have
been created by different
authors. The authors of the
patent US-6344596-B1 are not
the same of the cited
references.
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66 AAT, Human a-1-antitrypsin No A01395.1 Synthetic WO-1990-005188-A1 e
Silkworm 67 eGFP, enhanced green
fluorescent protein
No e cDNA US-7459599-B2 The patent is referred to the
initial invention
68 A2S814, spider silk protein No JB815849.1 cDNA US-2013-0212718-A1 In the patent, there are also
other sequences that have been
used in the different
experiments.
69 Synthetic silkworm fibroin gene No e Synthetic e The gene described here is a
synthetic gene obtained by
fusing part of silkworm fibroin
gene with DNA fragments
coding for active sites of
collagen or fibronectin proteins
70 CRP, canine C-reactive Protein No e cDNA US-8865966-B2 Sequence available in the
patent (SEQ ID No 6)
71 TRACP5, Human tartrate-
resistant acid phosphatase 5
No GZ833686.1 Synthetic US-8426674-B2 No publication, only patent
Trout 72 FST, follistatin No FJ185129.1 cDNA e
Tilapia 73 Humanized tilapia insulin No AR252279 Synthetic US-6476290-B1 Sequence available in the
patent (SEQ ID Nos 6 and 7)
Zebrafish 74 GFP, green fluorescent protein No GX731578 Genomic US-8378169-B2 GX731578 refers to the MLC2f
promoter region, that is the
most important part of the GM
cassette, as it allows tissue-
specific expression of
fluorescent proteins.
1To be reconstructed in silico.
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Table 3. Examples of animal species-specific PCR markers used in
food authentication. The species, location and identity of the PCR
targets, and amplicon size are listed along with the respective ref-
erences. References to literature for each entry in the table can be
found in the supplemental material. Note that most detection
methods use mitochondrial DNA targets.
Species Target origin ID Gene Amplicon
size (bp)
Chicken Mitochondrial 75 D-loop 256
Mitochondrial 76 ND5/Cytochrome b 117
Mitochondrial 77 Cytochrome b 106
Cow Mitochondrial 78 D-loop 513
Mitochondrial 79 12S 252
Mitochondrial 80 Cytochrome b 120
Mitochondrial 81 12S 256
Donkey Mitochondrial 82 ND2 145
Mitochondrial 83 ND2 183
Duck Mitochondrial 84 D-loop 292
Emu Mitochondrial 85 Cytochrome b 229
Goat Mitochondrial 86 12S 117
Mitochondrial 87 12S 326
Haddock Nuclear 88 transferrin 72
Halibut Nuclear 89 5S 368
Horse Mitochondrial 90 ATPase 8/6 153
Mitochondrial 91 ATPase 8/6 147
Mitochondrial 92 Cytochrome b 76
Ostrich Mitochondrial 93 Cytochrome b 543
Pig Mitochondrial 94 D-loop 835
Mitochondrial 95 ND5 227
Mitochondrial 96 Cytochrome b 131
Mitochondrial 97 ND5 115
Pigeon Mitochondrial 98 D-loop 401
Seagull Mitochondrial 99 ND2 94
Sheep Mitochondrial 100 12S/16S 172
Mitochondrial 101 t-glu/Cytochrome b 119
Mitochondrial 102 Cytochrome b 95
Sole nuclear 103 ITS1 116
nuclear 104 5S 187
Tuna Mitochondrial 105 16S 63
Mitochondrial 106 16S 130
Wallaroo Mitochondrial 107 Cytochrome b 205
Table 4. Common processed food ingredients from animal origin.
Ingredients marked with a* may also be derived from plants.
Ingredient Origin
Albumin Egg whites
Casein (caseinate) Milk protein
Gelatin Bones, cartilage, tendons, and skin
Glucose (dextrose)* Animal tissues and fluids
Glycerides (mono-, di-,
and triglycerides)
Animal fat
Isinglass Air bladder of freshwater fish
Lactose (saccharum
lactin, D-lactose)
Milk sugar
Lecithin* Animal tissues and egg yolks
Lutein* Egg yolks
Oleic acid (oleinic acid) Tallow
Pepsin Pig stomach
Stearic acid
(octadecanoic acid)
Tallow
Vitamin A (A1, retinol)* Egg yolks, fish liver oil
Vitamin D3 Fish liver oils
172 A. Lievens et al. / Trends in Food Science & Technology 44 (2015) 159e176may vary between tissues, fruits and seeds may be
(partially) haploid, etc.) a large body of practical experi-
ence currently justifies its use (Berdal & Holst-Jensen,
2001; Corbisier et al., 2007; Trapmann, 2006; Trapmann,
Corbisier, Schimmel, & Emons, 2010) and its existence
as an official recommendation from the European Commis-
sion (EC 2004/787/EC, 2004).
In animals, there are again several biological facts that
complicate the assumption of equivalence between DNA
ratio and mass percentage, the most straightforward
relating to the nature of muscle tissue. During embryonic
development, myoblasts fuse to form multinucleated myo-
fibers. Postnatal growth of skeletal muscle happens mainly
by increases in length and width of the muscle fibres and
not by an increase of the number of muscle fibres
(Rehfeldt, Fiedler, Dietl, & Ender, 2000) (and therefore,
in the number of cell nuclei). Yet, there is significant post-
natal DNA accumulation in muscle tissue (Allen, Merkel,& Young, 1979) in so-far that there appears to be a quite
linear relation between the number of nuclei and the muscle
mass (Trenkle, DeWitt, & Topel, 1978), relating to the large
population of satellite cells that are associated with muscle
tissue (Mauro, 1961; Moss & Leblond, 1971).
Transferability of the observed DNA percentages to
ingredient weight ratios thus seems likely but will have to
be confirmed and validated before this assumption can be
put to practice in quantifying food and feed for their GM
animal content. As an additional complication, ‘fat’ is often
regarded as a separate ingredient for certain food products.
On DNA basis however, the distinction between different
tissues is not readily made and in practice it may only be
possible to distinguish between ingredients if they originate
from different (animal) species.
GM animal product derivatives
Next to samples that are either pure meat or have meat
as their main ingredient, there are a large number of pro-
cessed food products that contain animal derivatives (see
Table 4 for a list of common ingredients derived from ani-
mals). Although the DNA content of food has been of
increasing interest to control authorities worldwide, data
that show which food or food fractions still contain DNA
are not readily available. As a consequence, the degree to
which a single animal derivative ingredient is detectable
by DNA based methods in a sample (if at all) is currently
not known and is likely to differ between products and in-
gredients. In such cases, the detection of GM animal con-
tent and its quantification may be more difficult and/or
require specific DNA extraction methods or entirely
different approaches.
PCR inhibition and DNA degradation
Many problems of sensitivity and repeatability in the
field of real-time PCR have to do with the quality of the
173A. Lievens et al. / Trends in Food Science & Technology 44 (2015) 159e176extracted DNA and its ability to sustain an efficient PCR re-
action. Maximal reaction efficiency is rarely guaranteed
due to the possible presence of so-called PCR inhibitors
(Bessetti, 2007) which limit reaction efficiency. These in-
hibitors generally act by direct interaction with DNA or
interference with the polymerases (Opel, Chung, &
McCord, 2010). In addition, DNA polymerases have ionic
requirements that can be the target of inhibition.
These problems are not limited to GM animal samples
and strongly depends on where in the processing chain
the sampling takes place since the prime source of inhibi-
tors are the samples themselves. In most cases these chem-
icals are co-extracted with the DNA and additional
purification steps are required to reach a sufficient level
of DNA purity. Another source of inhibitors are the re-
agents used during sample processing and DNA extraction.
These include high concentrations of KCl, NaCl and other
salts, ionic detergents (sodium deoxycholate, sarkosyl,
SDS), alcohols (ethanol, isopropanol), phenol, etc.
(Bessetti, 2007).
In addition to inhibitors, processing of foodstuffs further
reduces the DNA quality. Chemical and physical treatment
of the products (heat, pH, excessive grinding, etc.) result in
random fragmentation of the DNA (Kakihara, Matsufuji,
Chino, & Takeda, 2006). This reduction in the average
length of the DNA molecules makes their isolation more
challenging (Kakihara et al., 2006) and may cause loss of
amplification targets, thus decreasing sensitivity of detec-
tion and inducing bias in the quantification results
(Godalova, Bergerova, & Siekel, 2013).
Although there are no direct reasons to suspect the situ-
ation will be significantly different in animal samples
compared to other food samples, an assessment of which
methods work best on which matrices may be necessary
to validate the applicability of existing protocols. Espe-
cially during the initial stages of testing for GM animals,
the adoption of specific extraction methods and the design
of standard operating protocols may slow the pace of the
laboratory work.
Conclusion
We have counted at least 74 (on-going) attempts at ani-
mal modification, of which about half are designed for use
as livestock. Amongst the latter, at the majority are in-
tended for direct release onto the food market (as meat or
meat product) as opposed to animals for wool or milk pro-
duction. The number of GM animals for which we were
able to find (partial) sequence information was 56. Of all
the genetically modified animals listed, there is currently
only one that is actually being brought into production
(AquaAdvantagesalmon).
These figures are testament of the increasing scientific
activity related to GM animals and of the development of
a growing number of early commercial products in all of
the categories defined (i.e. livestock, bioreactor, compan-
ion). Incidental contamination of the food chain with GManimal material or derived products will become increas-
ingly likely, more so once the commercial farming of
GM animals begins.
Detection and identification of GM materials (be it plant,
animal or microbial) in food and feed samples is, in princi-
ple, no problem as it can be assumed that every genome
contains relatively short (50e500 bp) characteristic se-
quences by which it can be distinguished from others and
that can be readily amplified using standard PCR approach.
Current methodology for the control of genetically modi-
fied organisms should be therefore be transferable and
perform comparably on animal derived products. However,
techniques for detection and identification of sub-species,
varieties, and specific tissues are not readily available in
control laboratories, but DNA targets for such tests may
be become available through the expansion of the genome
databases and on-going bioinformatic analysis efforts.
Accurate quantification of GM animal products, on the
other hand, requires a number of prerequisites to be ful-
filled. The assumption of equivalence between DNA target
ratio and weight percentage should be validated and certi-
fied reference materials must be available. In addition,
quantification on a per ingredient basis may complicated
by the classification of different parts of the animal as sepa-
rate ingredients. There are, however, several alternative
quantification strategies such as quantification on a ‘per
species’ base, or on a ‘per total animal content’ base.
Although the latter may complicate the assumption of
DNA/weight equivalence. Lastly, there are some particular
genetic constructs that may compromise accurate quantifi-
cation (mosaic animals, hemizygote animals, etc.).
Several of the challenges involved in the appearance of
GM animal derivatives on the international market may be
tackled by the further incorporation of novel techniques
into the routine testing work flow. Most notably, digital
(droplet) PCR and Next Generation Sequencing (NGS)
have the power to transform the current practice of quanti-
fication based on standard curves using well-defined tar-
gets. For instance, taxonomic profiling and classification
involves the computational analysis of (NGS) random
shotgun sequencing results from DNA isolated directly
from a sample for its species composition and abundance.
Current efforts for developing such algorithms are mainly
focussed on bacterial samples (Darling et al., 2014;
Dr€oge, Gregor, & McHardy, 2014; Gregor, Dr€oge,
Schirmer, Quince, & McHardy, 2014), but the principles
used for binning the sequences can be applied to higher
species as well. Similarly, a suitable dilution of the sample
DNA run in carefully constructed ddPCR multiplex condi-
tions may simultaneously characterize and quantify a sam-
ple for its species composition. Although in the latter case,
one can only find the species one is looking for, whereas
NGS analysis is usually only limited by the content of
the databases to which the results are compared.
In summary, at the base of a good enforcement systems
lies (I) correct, representative sampling and (II) analytical
174 A. Lievens et al. / Trends in Food Science & Technology 44 (2015) 159e176methods that allow reliable detection and quantification.
The latter is facilitated by the availability of correct
sequence information which allows the construction of
powerful screening methods and the prevention of cross-
reactivity of the detection methods that are to be installed.
(III) Another pivotal point is the availability of reference
materials. These allow validation of the detection methods
and the reliable quantification of GM-positive samples. We
see no issues as far as the detection of GM animals is con-
cerned. However, their quantification faces two challenges:
one relates to the search for single copy nuclear endogenes,
the other relates to the cases in which the animals are either
mosaic or not homozygous for the transgene. Whether the
latter are truly problematic can only be decided on a
case-by-case basis through thorough examination of their
complete sequence information.Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.tifs.2015.05.001.
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